Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results. Yang P, Birch D, Lauer A, Sisk R, et al. Am J Ophthalmol 2025;271:268-285.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yang P, Birch D, Lauer A, Sisk R, et al. Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results. Am J Ophthalmol 2025;271:268-285.
PMID: 39643074